GSK plc (GSK) Earnings Call Transcripts

GSK plc's Latest Earnings Call - May 28, 2026

In the Q1 2026 earnings call for GSK plc, management highlighted the promising results from the pivotal Phase III studies of bepirovirsen for chronic hepatitis B, which achieved a functional cure rate of 19% in the overall population and 26% in patients with baseline HBsAg levels below 1,000 IU/ml. Revenue for the quarter was $6.5 billion, with earnings per share (EPS) reported at $0.75, both inline with expectations. Management maintained guidance for the fiscal year, anticipating continued growth driven by the upcoming approval of bepirovirsen in October 2026, which could significantly expand the addressable market in hepatitis B treatment.

Reported metrics

Guidance from management

Management maintained guidance for the fiscal year, expecting continued revenue growth driven by the anticipated approval of bepirovirsen in October 2026.

What management said

Yes. And I'm happy to address also the treated population. So the average that we have shown you today, meaning 68% of the treated population is less than 3,000 and 45% is less than 1,000, is the average across the 5 major markets, meaning U.S., China, Japan, EU5 and Germany. But there is variability from market to market. So for instance, in the less than 3,000 population, the average across those markets is 68%....

Yes. Sachin, I would just add on the testing. Testing in the U.S. is available. This is not some novel test that is not available. And just from the execution perspective going into the launch, it's clearly our priority to make sure that physicians, whenever they want to use it, will be able to use it. It's just that the testing so far was not needed for diagnosis, treatment or anything like that. And therefore, i...

What analysts pressed on

Analysts raised concerns about the efficacy of bepirovirsen in the 1,000 to 3,000 IU/ml subgroup, questioning whether the drug would be effective enough to justify its use compared to existing treatments. Additionally, there were inquiries about the safety monitoring requirements and how they would translate into real-world settings.

Main topics on the call

• Functional Cure Rates — Bepirovirsen achieved a functional cure rate of 19% in the overall patient population and 26% in those with baseline HBsAg levels below 1,000 IU/ml, a significant improvement over the 0% rate in the placebo group. Manage...
• Regulatory Approvals — GSK expects regulatory approval for bepirovirsen in the U.S., China, and Japan by October 2026, following Breakthrough Therapy and Priority Review designations. This approval is seen as a major catalyst for growth, with ...
• Market Opportunity — Management highlighted the large unmet need in chronic hepatitis B treatment, with approximately 240 million people affected globally. The potential market size was emphasized, particularly in the U.S. and China, where t...
• Safety Profile — The safety profile of bepirovirsen was deemed acceptable, with adverse events leading to permanent discontinuation at only 3%. Management indicated that transient ALT increases were associated with higher chances of achi...

Read the full GSK plc transcript (May 28, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 78 GSK plc earnings call transcripts on record, spanning January 14, 2020 to July 28, 2026. Based on this history, GSK plc reports quarterly. The most recent call on file is dated July 28, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

GSK

Exchange

LSE

Country

GB

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

78

First call

January 14, 2020

Most recent

July 28, 2026

Reporting cadence

quarterly